| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| VAG0157-2 | 7 days | 2 µg | $120.00 |
Select product before adding to cart
|
||
| VAG0157-10 | 7 days | 10 µg | $400.00 | |||
| VAG0157-100 | 7 days | 100 µg | $2,880.00 |
Product Overview | |
| Name | H1N1 Solomon Islands |
|---|---|
| Description | |
| H1N1 Influenza-A Virus Solomon Islands/03/06 Recombinant | |
| Introduction | |
| H1N1 is a subtype specie of Influenza A virus. H1N1 Influenza Virus has mutated into various strains such as the Spanish Flustrain, mild humanflu strains, endemic pigstrains, and various strains found in birds. The Influenza A Virus is a globular particle about 100nm in diameter, sheathed in a lipid bilayer derived from the plasma membrane of its host. Studded in the lipid bilayer are two integral membrane proteins some 500 molecules of hemagglutinin ("H") and some 100 molecules of neuraminidase ("N"). Within the lipid bilayer are 3000 molecules of matrix protein and 8 pieces of RNA. Each of the 8 RNA molecules is associated with many copies of a nucleoprotein, several molecules of the three subunits of its RNA polymerase some "non-structural" protein molecules of uncertain function. | |
| Physical Appearance | |
| Sterile Filtered colorless solution. | |
| Formulation | |
| The H1N1A/Taiwan/1/86 solution contains STE, 0.1% sodium azide (NaN3) and 0.005% thimerosal. | |
| Stability | |
| A/Taiwan/1/86 although stable 4°C for 4 weeks, should be stored below -18°C. Please prevent freeze-thaw cycles. | |
| Purity | |
| Greater than 90.0% as determined by SDS-PAGE. | |
| Inactivation | |
| Thimerosal and beta propiolactone treatment This product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work. | |
| Immunological Activity | |
| Tested with anti-influenza A monoclonal antibodies in ELISA. Serological studies of influenza A virus, immunogen for antibody production. | |
| Precautions | |
| H1N1 Solomon Islands is for research use only and not for use in diagnostic or therapeutic procedures. | |
References |
1. Title: Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection Publication : The Rockefeller University Press , doi: 10.1084/jem.20101352 © 2011 Wrammert et al. Link : H1N1 Solomon Islands prospec publication 2. Title :Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. Publication :The Journal of Clinical Investigation http://www.jci.org Volume 120 Number 5 May 2010. Link : H1N1 Solomon Islands Virus prospec publication |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team